Paris:VLA

Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate

Antibody levels remained well above baseline across all six serotypes and age groups sixth month after third yearly booster doseNo…

2 weeks ago

Valneva Announces Removal of FDA-Recommended Pause on Use of Chikungunya Vaccine IXCHIQ in Elderly and Updates to the Prescribing Information

Saint Herblain (France), August 7, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced…

4 months ago